MiR-133a can also attenuate cardiac hypertrophy by repressing the expression of serum response factor (SRF) and cyclin D2, both of which exacerbate aberrant cardiomyocyte proliferation and cardiac dysfunction [55]. Here, SRF is linked to cardiac hypertrophy.